Skip to NavigationSkip to content

Top Ten most popular articles on Pharmafile.com this week!

Published on 14/12/18 at 11:05am

Business seemed to be the theme this week as Akorn’s acquisition of Fresenius fell through, while Boehringer announced a restructuring through which 300 jobs would be lost. However our top story covered Novartis’ CEO Vasant Narasimhan’s comments on creating a more millennial friendly culture within the Swiss multinational.

Nevertheless our feature on developments being made in the area of MDMA-assisted psychotherapy was popular after positive Phase 2 results were released in November of this year.

Check out this week’s ten most popular stories on Pharmafile.com!

10. Trump administration block NIH researchers from using foetal tissue, disrupting research to cure HIV

The Trump Administration has halted the acquisition of new human foetal tissue for use in experiments conducted by NIH researchers, thus disrupting research into a cure for HIV.

9. Akorn CEO resigns after $4.3bn Fresenius deal falls through

The CEO of American generics firm Akorn Inc has stepped down following a ruling from the Delaware Supreme Court declaring that a rapid downturn in Akorn’s business was reason enough for German company Fresenius to walk away from a $4.3 billion dollar acquisition.

8. WHO confirm Tanzania FDA as Africa's first well-functioning regulatory body

Tanzania has become the first country in Africa to achieve a well-functioning regulatory system for medical products, according to the World Health Organization (WHO).

7. Feature – Psychedelic therapy: A new approach to mental health

In November 2018, a Phase 2 clinical trial found that 76% of patients who underwent MDMA-assisted psychotherapy no longer had PTSD, twelve months after undergoing treatment. Louis Goss looks into the process through which an underground therapy entered FDA approved clinical trials.

6. Atopic dermatitis market set to almost triple in value over next 10 years

The atopic dermatitis (eczema) market is expected to reach $18.3 billion by 2027, according to analytics firm GlobalData.

5. Generics firms investigated for their involvement in the 'largest cartel in the history of the United States'

At least 16 generic drugmakers are being investigated for their involvement in what has been described as the “largest cartel in the history of the United States”.

4. Boehringer's France restructure will cull over 300 jobs

Boehringer Ingelheim is set to follow in the recent steps of Sanofi with the announcement of a cull of over 300 employees in France – around 10% of the company’s total workforce in the country.

3. Pfizer announces new UK Managing Director

New York City-based multinational Pfizer has announced the appointment of Ben Osborn to the role of managing Director in the UK and Cluster Lead Europe within Pfizer’s Established Medicines business.

2. Pfizer's palbociclib most commonly used breast cancer drug in clinical trials

Pfizer’s palbociclib is the most commonly used breast cancer drug in clinical trials, according to analytics firm GlobalData.

1. Novartis CEO calls for cultural shift to cater for millennial generation

The CEO of Swiss multinational Novartis has said that he wants to ‘un-boss’ the multi-billion pound company while relaxing the firm’s rules by allowing employees to wear jeans to work.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches